Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALN-ANG3 in Healthy Volunteers With Hyperlipidemia
NCT06452771Phase 1Active, not recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jun 2024
- Primary completion
- Dec 2026
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ALN-ANG3 in hyperlipidemia (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 323 days and Severity of Treatment-Emergent Adverse Events at 323 days. Started Jun 2024; status: active, not recruiting.
02
Drugs
ALN-ANG3
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on NCT06452771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06452771.